ExodusPoint Capital Management’s C4 Therapeutics CCCC Stock Holding History

ExodusPoint Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$125K	Sell	47,507 -14,658	-24%	-$34.5K	﹤0.01%	1425
2025 Q4	$119K	Buy	+62,165	New	+$147K	﹤0.01%	1427
2025 Q1	–	Sell	-59,654	Closed	-$215K	–	1511
2024 Q4	$215K	Buy	+59,654	New	+$297K	﹤0.01%	1351
2023 Q2	–	Sell	-10,551	Closed	-$33K	–	1881
2023 Q1	$33K	Buy	+10,551	New	+$62.1K	﹤0.01%	1677
2022 Q3	–	Sell	-35,197	Closed	-$265K	–	1916
2022 Q2	$265K	Buy	+35,197	New	+$310K	﹤0.01%	1576

Other funds holding CCCC

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ExodusPoint Capital Management's CCCC Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its C4 Therapeutics (CCCC) stake by 24% in Q1 2026, selling an estimated $34.5K and leaving 47,507 shares worth $125K. The position accounts for ﹤0.01% of the portfolio, ranked #1425.

ExodusPoint Capital Management first reported a position in CCCC in Q2 2022 and has held it in 5 quarters since. The position peaked at $265K in Q2 2022. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

ExodusPoint Capital Management held 47,507 shares of C4 Therapeutics worth $125K as of Q1 2026.
ExodusPoint Capital Management sold 14,658 C4 Therapeutics shares in Q1 2026, an estimated $34.5K.
C4 Therapeutics made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1425 holding.
ExodusPoint Capital Management first reported a position in C4 Therapeutics in Q2 2022 and has held it in 5 quarters since.
ExodusPoint Capital Management's C4 Therapeutics position peaked at $265K in Q2 2022.
123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.